VOYAGER'S ALZHEIMER'S TREATMENT SHOWS PROMISE

A A

VP4896, Voyager Pharmaceutical's lead product, has shown promise in a Phase II clinical trial, the company reported.

Leuprolide acetate, the active ingredient in VP4896, stabilized the cognitive and functional decline of women with mild-to-moderate Alzheimer's disease when used in conjunction with standard Alzheimer's therapy, the company said.

Leuprolide acetate has been used for over 20 years as a treatment for prostate cancer.